Last reviewed · How we verify
Lactobacillus and Bifidobacterium
Lactobacillus and Bifidobacterium, marketed by the Masonic Cancer Center at the University of Minnesota, holds a niche position in the probiotic market. The key composition patent expiring in 2028 provides a significant period of exclusivity, enhancing the product's competitive edge. The primary risk lies in the lack of clear revenue data and key trial results, which may affect investor confidence and market adoption.
At a glance
| Generic name | Lactobacillus and Bifidobacterium |
|---|---|
| Sponsor | Masonic Cancer Center, University of Minnesota |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Probiotics on Respiratory Tract Infections in Children: A Randomized, Placebo-Controlled Interventional Study (PHASE2)
- Efficacy of Symprove Probiotics in Coeliac Disease (NA)
- Effects of Probiotic Supplementation on Stress and Anxiety in Students (NA)
- Synbiotic Supplementation and Inflammation in Predialysis Chronic Kidney Disease (NA)
- The Efficacy and Safty of FMT in Patients With CID (PHASE1, PHASE2)
- Effect of a Probiotic on the Urinary Tract Microbiota of Participants With Recurrent Urinary Tract Infection. (NA)
- Study to Evaluate the Efficacy of Lactobacillus Crispatus M247 in the Prevention and Treatment of Recurrent Urinary Tract Infections (NA)
- Prospective Study to Determine the Factors Influencing Infant Colic (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: